Does human semen contain a functional haemostatic system?

Summary

There is already evidence that a few components of the haemostatic system exist in semen. If these comprise a functional system, they may have a role in seminal clotting and liquefaction processes and ultimately may influence fertility. What might be expected in semen as collected from fertility clinics i.e., after having both coagulated and subsequently liquefied is uncertain. It does however still contain significant amounts of Tissue Factor (TF) although its effect on semen quality remains poorly understood. The present study analyses semen for Tissue Factor Pathway Inhibitor (TFPI). Measurements were made in seminal plasma, swim-up sperm and prostasomes and its relationship with conventional fertility parameters assessed. TFPI antigen levels in seminal plasma were measured in a total of 176 subjects using an Enzyme-linked immunosorbent assay (ELISA). These include sub-fertile (n=37), normally fertile (n=40), fertile sperm donor (n=34), vasectomized subjects (n=65) and in a further group defined by normality in several parameters derived from the World Health Organization (WHO) fertility criteria and termed “pooled normal semen parameters” (PNSP). For characterization studies, both TFPI activity and antigen were measured on whole semen, swim-up sperm and prostasome-rich fraction (n=5). TFPI levels were significantly higher in normal men as compared to sub-fertile (P<0.01) or vasectomized subjects (P<0.001). TFPI levels were even higher in the donor quality semen and the PNSP group. TFPI levels also correlated with semen liquefaction time, normal semen viscosity, sperm progression, percentage of motile sperm and sperm counts (density). In conclusion, the present finding substantiates the concept of an active clotting system in human semen. TFPI could regulate the activity of abundant TF, as it does elsewhere. Given a functional set of coagulation factors in semen, the TF/TFPI balance might impinge on its liquefaction and hence on global fertility.

Keywords

Tissue Factor Pathway Inhibitor (TFPI) - human semen - fertility - novel finding

• References

• 1 Huggins C, Neal W. Coagulation and liquefaction of semen. Proteolytic enzymes and citrate in prostatic fluid. J Exp Med 1942; 76: 527-41.
• 2 Tauber PF, Zaneveld LJD, Propping D. et al. Components of human split ejaculates. II. Enzymes and proteinase inhibitors. J Reprod Fertil 1976; 46: 165-71.
• 3 Mandal A, Bhattacharyya AK. Grouping the ejaculates according to the degree of coagulation and the relationship to the levels of choline and cholinesterase. Int J Androl 1986; 9: 407-15.
• 4 Masaki J. Biochemistry of semen. In: Spermatology. Mohri H, Morisawa M, Hoshi M (Eds). Tokyo, University of Tokyo Press 1992; 121-37.
• 5 van Wersch JWJ, Ubachs JHM, Dalaere KPJ. Fibrinolysis and coagulation markers in seminal plasma before and after vasectomy. Fibrinolysis 1993; 7: 135-8.
• 6 Españ F, Gilabert J, Estellés A. et al. Functionally active protein C inhibitor/plasminogen activator inhibitor- 3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991; 64: 309-20.
• 7 Carson SD, De Jonge CJ. Activation of coagulation factor X in human semen. J Androl 1998; 19: 289-94.
• 8 Fareed J, Callas DD, Hoppensteadt D. et al. Tissue factor antigen levels in various biological fluids. Blood Coagul Fibrinolysis 1995; 6: 32-6.
• 9 Fernández JA, Heeb MJ, Radtke K-P. et al. Potent blood coagulant activity of human semen due to prostasome- bound tissue factor. Biol Reprod 1997; 56: 757-63.
• 10 Brody I, Ronquist G, Gottfries A. Ultrastructural localisation of the prostasome-an organelle in human seminal plasma. Upsala J Med Sci 1983; 88: 63-80.
• 11 Nemerson Y, Bach R. Tissue factor revisited. Prog Hemost Thromb 1982; 6: 237-61.
• 12 Nemerson Y. Tissue Factor: Then and now. Thromb Haemost 1995; 74: 180-4.
• 13 Broze GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
• 14 Broze GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6: 7-13.
• 15 Skibinski G, Kelley RW, Harkiss D. et al. Immunosupression by human seminal plasma-extracellular organelles (prostasomes)modulate activity of phagocytic cells. Am J Rerod Immunol 1992; 28: 97-103.
• 16 Lwaleed BA, Greenfield R, Stewart A. et al. Seminal clotting and fibrinolytic balance: a possible physiological role in the male reproductive system. Thromb Haemost 2004; 92: 752-66.
• 17 World Health Organization: WHO Laboratory Manual for the examination of human semen and semen-cervical mucus interaction. 2000. Cambridge: Cambridge University Press;
• 18 Polak B, Daunter B. seminal plasma biochemistry. IV: enzymes involved in the liquefaction of human seminal plasma. Int J Androl 1989; 12: 187-94.
• 19 Ronquist G, Nilsson BO. Prostasomes. Wennergren International Series. London: Portland Press; 2002
• 20 Matsuda Y, Shimokawa K, Katayama M. et al. Blood coagulation factor X (FX) in human seminal plasma. Arch Androl 2002; 48: 295-300.
• 21 Park JY, Yoshimara Y, Nozawa S. et al. Fibrinogenlike substance and thrombin like enzyme in human seminal plasma: coagulation of human semen. Arch Androl 1997; 38: 29-36.
• 22 Yamamuro M, Wada H, Kumeda K. et al. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1998; 6: 491-7.
• 23 Moghissi KS, Wallach EE. Unexplained infertility. Fertil Steril 1983; 39: 5-21.
• 24 Rümke P. The origin of immunoglobulins in semen. Clin Exp Immunol 1974; 17: 287-97.
• 25 Mandal A, Bhattacharyya AK. Relationship between the coagulation-liquefaction property of human ejaculates and their volume, sperm count and motility. Clin Reprod Fertil 1987; 5: 367-71.
• 26 Elzanaty S, Richthoff J, Malm J. et al. The impact of epididymal and accessory sex gland function on sperm motility. Hum Reprod 2002; 17: 2904-11.
• 27 Zhao Y, Vlahos N, Wyncott D. et al. Impact of semen characteristics on the success of intrauterine insemination. J Assist Reprod Genet 2004; 21: 143-8.
• 28 Mahony MC, Alexander NJ. Sites of antisperm antibody action. Human Reprod 1991; 6: 1426-30.
• 29 D’Cruz OJ, Haas Jr GG, Wang B. et al Activationof human complement by Ig Gantispermantibody and the demonstration of C3 and C5b-9-mediated immune injury to human sperm. J Immunol 1991; 146: 611-20.
• 30 Ronquist G, Nilsson BO, Hjerten S. Interaction between prostasomes and spermatozoa from human semen. Arch Androl 1990; 24: 147-57.
• 31 Dong L, Peng Y, Wang R. Expression and its clinical significance of tissue factor pathway inhibitor and antithrombin-III in patients with hepatic inflammatory diseases. Chung Hua Kan Tsang Ping Tsa Chih 1999; 7: 224-5.
• 32 Koudsi B, Chatman DM, Ballinger BA. et al Tissue factor pathway inhibitor protects the ischemic spinal cord. J Surg Res 1996; 63: 174-8.
• 33 Chen D, Riesbeck K, McVey JH. et al. Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. Xenotransplantation 2001; 8: 258-65.
• 34 Nakamura Y, Nakamura K, Ohta K. et al. Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. Basic Res Cardiol 2002; 97: 198-205.
• 35 Creasey AA, Chang AC, Feigen L. et al Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. JClin Invest 1993; 91: 2850-6.